Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.76 USD | +0.75% | +26.96% | +14.66% |
09:45am | Elekta to Buy Philips Healthcare's Treatment Planning Patent Portfolio | MT |
05-02 | PHILIPS NV : DZ Bank reiterates its Neutral rating | ZD |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company's profit outlook over the next few years is a strong asset.
Weaknesses
- With an expected P/E ratio at 51.84 and 22.29 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.66% | 24.21B | - | ||
+8.36% | 218B | B | ||
+7.43% | 183B | B- | ||
+13.35% | 134B | B- | ||
+26.35% | 106B | A- | ||
-1.33% | 61.12B | A- | ||
+4.81% | 50.89B | B+ | ||
+0.37% | 40.3B | A | ||
+3.00% | 35.53B | - | ||
+26.59% | 32.05B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PHIA Stock
- PHG Stock
- Ratings Philips NV